Skip to main content
SENS logo

SENS · Senseonics Holdings, Inc.

Track SENS — free
$8.79 -0.12 (-1.29%)
Market Cap
$487.82M
Shares
54.78M
Volume · Nov 19 1.33M Avg daily vol (3M) 816.28K

Price & Indicators

 

Key stats

Close
$8.91
Open
$9.80
Day range
$8.76–10.15
52-week closing range
$4.86–10.90
Average volume, 30 days
959K
Short interest
4.7M · 8.7% of shares · 7.8 days
Short volume, last session
37%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

Mar 1, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 10
Investor event
Gemini Targeted for 2027, Freedom for 2028

Senseonics targets Gemini for 2027 and Freedom for 2028, expects 2026 cash burn of about $120 million, and anticipates a margin profile north of 60% next year, with Freedom margins north of 70%.

5 source passages
So Gemini is targeted for 2027. And importantly, we're absolutely on track for 2028 to deliver the Freedom product. Yeah, so for 2026, we expect to burn about $120 million, so $10 million a month for simplicity. In 2027, we expect revenue to continue to grow. With the strong margin profile we have, north of 60% next year, that'll continue to contribute to those operating expenses, and we'll see some operating leverage in 2027. because the margin profile of the Freedom product we expect to be north of 70%, and that really will be the catalyst for our cash flow break-even. Open the document at this passage
Nov 9
Earnings call
Revenue doubles as full-year guidance raised

Senseonics reported third-quarter 2026 revenue of $19.6 million, up approximately 140%, and raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million.

3 source passages
Good day, everyone, and welcome to Senseonics' third quarter, 2026 earnings call. Net revenue for the third quarter was $19.6 million, an increase of approximately 140% compared to $8.1 million in the third quarter of 2025. Given the strength we saw in our sales again this quarter, we're raising our full-year 2026 revenue guidance to $68 million to $70 million, from our prior range of $62 million to $66 million. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises to $19.6 million as gross margin reaches 61.7%

Senseonics reported revenue of $19.6 million for the three months ended September 30, 2026, up from $8.1 million, while gross margin improved to 61.7% from 42.8%.

Revenue $19.56M ▲ 141.6% Net loss $32.68M Diluted EPS -$0.50
Read from the MD&A section
2 source passages
Our total revenue increased to $19.6 million for the three months ended September 30, 2026, compared to $8.1 million for the three months ended September 30, 2025, an increase of $11.5 million. Gross profit as a percentage of revenue, or gross margin, was 61.7% and 42.8% for the three months ended September 30, 2026, and September 30, 2025, respectively. Open the document at this passage
Nov 9
Current report 8-K
Revenue grows 140% as 2026 outlook rises

Senseonics Holdings, Inc. generated third quarter revenue of $19.6 million, up approximately 140% year-over-year, and raised full-year 2026 revenue guidance to $68 million to $70 million. Gross margin was approximately 62%.

Financial results
3 source passages
Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98% Achieved gross margin of approximately 62% during Q3, and raising full-year gross margin guidance to more than 60% from 58% to 61% Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$60.01M
Trailing 12 months
Net income (TTM)
−$122.53M
Trailing 12 months
Revenue growth YoY
+141.6%
Year over year
Operating margin
-201.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-23.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$72.10M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+46.2%
Year over year · more shares
Price change (1Y)
+57.9%
Trailing year
Short interest
8.7%
Latest settlement · 7.8 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. Third-quarter revenue grew approximately 140%, with full-year revenue and gross-margin guidance raised, while EON Care expanded and the Beta Bionics and Freedom initiatives advanced. The company remained loss-making as R&D and SG&A increased, operating expenses are expected slightly above the prior guidance range, cash use is expected at the high end of the prior range, and Europe is expected to represent approximately 15% of full-year revenue, down from 20%.

Bullish
  • + Third-quarter revenue reached $19.6 million, up approximately 140% year over year.
  • + Full-year 2026 revenue guidance was raised to $68 million-$70 million from $62 million-$66 million.
  • + Third-quarter gross margin was approximately 62%, and full-year gross-margin guidance was raised to more than 60%.
  • + The EON Care network exceeded its 100-inserter year-end goal and is expected to reach approximately 120 inserters by year-end.
  • + Senseonics announced a Beta Bionics partnership to integrate Eversense 365 with the iLet Bionic Pancreas, with commercial launch planned for the fourth quarter of 2026.
  • + Senseonics initiated the first-in-human study of Freedom, an investigational CGM without an on-body component.
Bearish
  • − Net loss widened to $32.7 million, or $0.50 per share, from $19.5 million, or $0.43 per share.
  • − Research and development expense increased to $11.7 million from $7.8 million.
  • − Selling, general and administrative expense increased to $32.3 million from $15.3 million.
  • − Full-year operating expenses are expected to come in slightly above the previous guidance range of $150 million-$160 million.
  • − Four-year cash utilization is expected at the high end of the prior range, or approximately $120 million.
  • − Europe is expected to represent approximately 15% of full-year revenue, down from the previously discussed 20%.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +21%
above
Price vs 50-day avg −4%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 67%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +20%
trailing
6-month return +30%
trailing
YTD return +61%
this year
Relative strength +36%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +38 funds added
Insider flow Accumulating
Net +$175.9K over 90 days · 0% sells
Short interest Falling
8.65% of shares out · ▼ -2.7% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
133 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Excellent
Revenue growth +20%
Y/Y
Gross margin 96%
expanding
EPS growth +34%
Y/Y
Balance sheet $4.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −42%
past year
ATR 11.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the Earnings Call filed Nov 9, 2026
full-year 2026
Full-year revenue Raised $68M – $70M
Aug 6, 2026 $62M – $66M changed to Nov 9, 2026 $68M – $70M
prior FY $35.26M midpoint +95.7% Y/Y
Europe share of full-year revenue 15%
not stated
Gross margins for the Freedom products at least 70%
Previous outlook earlier release · from the Earnings Call filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Operating expenses · full-year 2026 $150M – $160M
Cash utilization · full-year 2026 $110M – $120M
Full-year gross margin · full-year 2026 58% – 61%
Guided vs delivered · last 6 settled
Global net revenue Full Year 2024
guided $22M – $24M
$22.47M In line
Global net revenue full year 2023
guided $20M – $24M
$22.39M In line
Global net revenue full year 2022
guided $15M – $17M
$16.39M In line
Global net revenue 2021
guided $12M – $15M
$13.68M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+21% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
67% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +38 funds added
Insider flow Accumulating
Net +$175.9K over 90 days · 0% sells
Short interest Falling
8.65% of shares out · ▼ -2.7% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
133 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $9 · 67% Range high $11
vs 200-day avg +21% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, restricted cash and short-term investments $126.6M As of September 30, 2026 —
EON Care network inserters 100 third quarter —
Principal borrowings outstanding under the Hercules Capital facility $55M As of September 30, 2026 —
Share of third quarter Eversense insertion procedures performed by EON Care inserters 40% third quarter —
Capital raised during Q2 $100M Q2 2026 —
Eon Care nurses 90 Q2 2026 —
Equity proceeds raised in Q2 $90M Q2 2026 —
Expanded Hercules Capital facility capacity $140M Q2 2026 —
Share of Eversense insertion procedures via Eon Care 40% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SENS
Senseonics Holdings, Inc.
this stock
$487.82M +61.3% +19.8% — 8.7%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
133
% held
43.1%
Net QoQ
+2.8M sh
Top holder
Sessa Capital IM, L.P.
Held Float
View
Held by Funds
Fund positions
92
View
Short & Settlement
Short Interest Falling
Shares short
4.7M
Days to cover
7.8d
Change
-132.2K sh
View
Short Volume
Short vol %
37%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$14.0K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
41.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$175.9K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$35.3M
Net income (FY)
$-69.1M
EPS diluted
$-1.66
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
21

Senseonics targets Gemini for 2027 and Freedom for 2028, expects 2026 cash burn of about $120 million, and anticipates a margin profile north of 60% next year, with Freedom margins north of 70%.

View
Proposed Sales
Value
$19.2K
Shares
30.9K
Filed
Sep 7, 2023
View
Exempt Offerings
Offering
$20.3M
Filed
May 29, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Senseonics and Beta Bionics Launc…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
SENS -11.3% +20.3% +30.2% -6.4% +61.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -5.9% +26.6% +35.8% -1.1% +56.3%
Key facts CIK 1616543 CUSIP 81727U303 13F (30d) 144 filings 126 filers Visit website Investor relations